Traditional Chinese medicine composition for treating polycystic ovarian syndrome

Abstract

The invention relates to the technical field of medicine, in particular to a traditional Chinese medicine composition for treating polycystic ovarian syndrome. The traditional Chinese medicine composition is prepared from the following raw medicines of, in parts by weight, 10 g-12 g of radix paeoniae rubra, 8 g-10 g of motherwort, 8 g-10 g of red flower, 12 g-15 g of rhizoma corydalis, 8 g-10 g of cortex moutan, 12 g-15 g of selfheal, 12 g-15 g of szechwan chinaberry fruit, 8 g-10 g of radix achyranthis bidentatae and 12 g-15 g of rhizoma cyperi. The traditional Chinese medicine composition is reasonable in prescription compatibility, rich in raw materials, stable in curative effect, safe, reliable and free of toxic and side effects, is effectively used for treating the polycystic ovary syndrome, and is an innovation of medicines for treating the polycystic ovary syndrome.

Description

Technical field [0001] The present invention relates to the field of medical technology, in particular a Chinese medicine composition for treating polycystic ovary syndrome. Background technique [0002] Polycysticovariansynyndrome (PCOS) is a disease with excessive and continuous non-explosion, with endocrine disorder syndrome related to reproductive and metabolic abnormalities, clinical symptoms have menstrual disorders, amenorrhea, infertility, Polymer, acne, etc. PCOS caused by pregnancy than 60% in childbearing age, and the early abortion rate is as high as 30% -50% after pregnancy, and is the most important reason for the infertility of childbearing age. Western medicine is the treatment of PCOS, using Krimfen and other promotion ovulation drugs, by blocking the positive, negative feedback effect of estrogen, reducing the secretion of the yellow body, reducing the synthesis and release of the androgen, increases follicle stimulation secretion, promoting Follow development. ...

AI Technical Summary

Problems solved by technology

Although the use of ovulation-stimulating drugs alone can help alleviate the persistent anovulatory symptoms caused by polycystic ovary syndrome and play a certain therapeutic role, it has no therapeutic effect on the endometrial receptivity of polycystic ovary syndrome. The low pregnancy rate and high miscarriage rate after ovulation therapy are closely related to the impediment of implantation of fertilized eggs. Therefore, the use of ovulation induction drugs alone has limited therapeutic effect on infertility caused by PCOS, and long-term use of ovulation induction drugs is prone to ovarian hyperstimulation syndrome, an increased incidence of pregnancy complications that prevents effective treatment of polycystic ovary syndrome

[0003] Western medicine often uses drugs such as clomiphene, letrozole, and chorionic gonadotropin to induce ovulation. Although the effect is quick, but the side effects are relatively large, and it will cause problems such as ovarian hyperstimulation, follicle luteinization, high ovulation rate and low pregnancy rate, and is not suitable. Long-term continuous use